Treatment

Copanlisib clinical trials

1 indexed studies · 0 currently recruiting

Active not recruitingPHASE2
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
This study is testing a new combination of medicines, Copanlisib and Rituximab, for a type of blood cancer called Marginal Zone Lymphoma (MZL). It aims to see if this chemotherapy-free treatment is effective and has fewer side effects than current options, especially for older patients.
For: Marginal Zone Lymphoma
Austria · Germany